Section Arrow
Quote
KALA.NASDAQ
- Kala BIO
Quotes are at least 15-min delayed:2024/12/24 13:09 EST
Last
 6.24
+0.24 (+4.00%)
Day High 
6.28 
Prev. Close
6 
1-M High
7.03 
Volume 
38.00K 
Bid
5.5
Ask
7.01
Day Low
6.0399 
Open
6.04 
1-M Low
5.67 
Market Cap 
27.66M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 6.09 
20-SMA 6.37 
50-SMA 6.43 
52-W High 9.25 
52-W Low 4.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-11.67/-6.65
Enterprise Value
63.65M
Balance Sheet
Book Value Per Share
1.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.09
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3853-0.0178-4.42%-- 
CMNDClearmind Medicine1.72+0.5+40.98%0.16PE
CEROCERo Therapeutics Holdings0.0623+0.0118+23.37%-- 
ATNF180 Life Sciences Corp2.9+1.03+55.08%0.23PE
RXRXRecursion Pharmaceuticals7.24+0.25+3.58%-- 
Quotes are at least 15-min delayed：2024/12/24 13:09 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.